BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 12, 2026
Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

Biopure’s Stock Rises on Blood Substitute Phase III Study Data

March 21, 2002
By Brady Huggett

Paion To Develop Millennium’s MLN519 Cardiovascular Product

March 15, 2002
By Brady Huggett
Millennium Pharmaceuticals Inc. decided to let someone else drive, or at least pay for the gas, in the development of its cardiovascular product, MLN519. (BioWorld Today)
Read More

Paion To Develop Millennium’s MLN519 Cardiovascular Product

March 15, 2002
By Brady Huggett
Millennium Pharmaceuticals Inc. decided to let someone else drive, or at least pay for the gas, in the development of its cardiovascular product, MLN519. (BioWorld Today)
Read More

MitoKor Eyes Public Markets, Files For Estimated $60M IPO

March 12, 2002
By Brady Huggett

MitoKor Eyes Public Markets, Files For Estimated $60M IPO

March 12, 2002
By Brady Huggett

Celgene Changing Course On Thalomid In Multiple Myeloma

March 8, 2002
By Brady Huggett
Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today)
Read More

Celgene Changing Course On Thalomid In Multiple Myeloma

March 8, 2002
By Brady Huggett
Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today)
Read More

Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod

March 1, 2002
By Brady Huggett
Centocor Inc.’s Remicade is inflating - both in uses and sales - having received a third approval in a rheumatoid arthritis indication. (BioWorld Today)
Read More

Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod

March 1, 2002
By Brady Huggett
Centocor Inc.’s Remicade is inflating - both in uses and sales - having received a third approval in a rheumatoid arthritis indication. (BioWorld Today)
Read More

ImClone Says FDA Might Accept Erbitux BLA With No New Trials

Feb. 28, 2002
By Brady Huggett
ImClone Systems Inc., after being dragged to scandalous depths not often seen in the biotechnology sector, bobbed to the surface Wednesday following its meeting with the FDA concerning the cancer drug Erbitux. (BioWorld Today)
Read More
View All Articles by Brady Huggett

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 12, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • LINC01116 has prognostic value in lung cancer, study shows

    BioWorld Science
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing